Amenorrhea in an Adolescent Female As a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis

Overview

Journal Patient Prefer Adherence

Date 2024 Nov 20

PMID 39564523

Authors

Yan Teng

Yi Tang

Yibin Fan

Xiaohua Tao

Yang Ding

Affiliations

Soon will be listed here.

Abstract

Atopic dermatitis (AD) is a common chronic inflammatory cutaneous disease. Upadacitinib, a selective JAK-1 inhibitor, has been approved as a systemic medication for moderate-to-severe AD in patients aged ≥12 years. Although previous studies have examined the safety profile of upadacitinib, this is the first report to describe a potential association between amenorrhea and upadacitinib or other JAK inhibitors. Herein, we report a rare adverse event of amenorrhea in an adolescent female patient who was treated with upadacitinib for AD. This case report expands the range of adverse events potentially associated with upadacitinib therapy.

References

Hagino T, Yoshida M, Hamada R, Saeki H, Fujimoto E, Kanda N . Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan. J Dermatolog Treat. 2023; 34(1):2276043. DOI: 10.1080/09546634.2023.2276043. View

Bieber T, Katoh N, Simpson E, de Bruin-Weller M, Thaci D, Torrelo A . Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatolog Treat. 2022; 34(1):2161812. DOI: 10.1080/09546634.2022.2161812. View

Mohrenschlager M, Demolli P, Schmidt V . How does atopic dermatitis in childhood and adolescence affect educational success?. J Eur Acad Dermatol Venereol. 2021; 35(9):1746. DOI: 10.1111/jdv.17518. View

Hagino T, Saeki H, Fujimoto E, Kanda N . Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study. J Dermatolog Treat. 2024; 35(1):2344591. DOI: 10.1080/09546634.2024.2344591. View

Simpson E, Paller A, Siegfried E, Boguniewicz M, Sher L, Gooderham M . Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2019; 156(1):44-56. PMC: 6865265. DOI: 10.1001/jamadermatol.2019.3336. View

Kowalska-Oledzka E, Czarnecka M, Baran A . Epidemiology of atopic dermatitis in Europe. J Drug Assess. 2019; 8(1):126-128. PMC: 6566979. DOI: 10.1080/21556660.2019.1619570. View

Brunner H, Akikusa J, Al-Abadi E, Bohnsack J, Boteanu A, Chedeville G . Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Ann Rheum Dis. 2024; 83(11):1561-1571. PMC: 11503147. DOI: 10.1136/ard-2023-225094. View

Fanouriakis A, Pamfil C, Sidiropoulos P, Damian L, Flestea A, Gusetu G . Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. Lupus. 2015; 25(6):627-36. DOI: 10.1177/0961203315622821. View

Guttman-Yassky E, Teixeira H, Simpson E, Papp K, Pangan A, Blauvelt A . Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021; 397(10290):2151-2168. DOI: 10.1016/S0140-6736(21)00588-2. View

10.

Blauvelt A, Teixeira H, Simpson E, Costanzo A, de Bruin-Weller M, Barbarot S . Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021; 157(9):1047-1055. PMC: 8340015. DOI: 10.1001/jamadermatol.2021.3023. View

11.

Teng Y, Zhong H, Yang X, Tao X, Fan Y . Current and Emerging Therapies for Atopic Dermatitis in the Elderly. Clin Interv Aging. 2023; 18:1641-1652. PMC: 10558003. DOI: 10.2147/CIA.S426044. View

12.

Palsson K, Slagor R, Flachs E, Norreslet L, Agner T, Ebbehoj N . Childhood atopic dermatitis is associated with a decreased chance of completing education later in life: a register-based cohort study. J Eur Acad Dermatol Venereol. 2021; 35(9):1849-1858. DOI: 10.1111/jdv.17346. View

13.

Tanei R, Katsuoka K . Clinical analyses of atopic dermatitis in the aged. J Dermatol. 2008; 35(9):562-9. DOI: 10.1111/j.1346-8138.2008.00524.x. View

14.

Navarro-Trivino F, Alcantara-Luna S, Dominguez-Cruz J, Galan-Gutierrez M, Ruiz-Villaverde R, Pereyra-Rodriguez J . Upadacitinib for moderate to severe atopic dermatitis. Immunotherapy. 2023; 15(11):799-808. DOI: 10.2217/imt-2023-0037. View

15.

Simpson E, Papp K, Blauvelt A, Chu C, Hong H, Katoh N . Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022; 158(4):404-413. PMC: 8908226. DOI: 10.1001/jamadermatol.2022.0029. View

16.

Lania A, Gianotti L, Gagliardi I, Bondanelli M, Vena W, Ambrosio M . Functional hypothalamic and drug-induced amenorrhea: an overview. J Endocrinol Invest. 2019; 42(9):1001-1010. DOI: 10.1007/s40618-019-01013-w. View